Neuren Pharmaceuticals LimitedASX: NEU

Acadia enters DAYBUE STIX distribution agreement in Japan

· Issued by Neuren Pharmaceuticals Limited via ASX

Filed with ASX · · 2 pages · English

Summary by 6ix AI

Neuren is entitled to receive significant milestone payments and royalties under its licensing agreement with Acadia. The announcement highlights Neuren's ongoing collaboration with Acadia and the potential for future product launches in Japan.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Neuren (NEU) – ASX Announcement 17 November 2026 Acadia enters exclusive distribution agreement for DAYBUE® STIX in Japan Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU)’s exclusive global partner for trofinetide, Acadia Pharmaceuticals (Nasdaq: ACAD), has announced that it has entered...

Neuren Pharmaceuticals Limited on 6ix

Story so far

Earlier from Neuren Pharmaceuticals

All Neuren Pharmaceuticals news releases